Rrx-001-211-01- A Phase II Study Of Rrx-001 In Platinum Refractory/Resistant Small Cell Lung Cancer, Egfr Tki Resistant Egfr+ T790m Negative Non-Small Cell
Posted Date: May 15, 2019
- Investigator: Davendra Sohal
- Specialties: Cancer, Lung Cancer, Oncology, Ovarian Cancer
- Type of Study: Drug
To evaluate Overall Survival (OS) and Overall Response Rate (ORR) of RRx-001 in patients with high-grade neuroendocrine carcinoma, non-small cell lung cancer, and ovarian cancer previously treated with a platinum based regimen.
Criteria:
To Be Eligible: Must Have Neuroendorcrine Carcinoma, Nsclc, Or Ovarian Cancer, Age 18 Or Older, Life Expectancy Over 12 Weeks, Nonpregnant/Breastfeeding
Keywords:
Lung Cancer, Ovarian Cancer, Neuroendocrine, Rrx001-211-01
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com